Frontlight ResearchEarly access
CompletedPhase 2
A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients
Key facts
- Who runs it
- Enlivex Therapeutics Ltd.
- Where
- Belgium, France, Israel, Netherlands, and Spain31 sites in 5 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 148 people enrolled
- Started
- 30 Nov 2020
- Ended
- 16 Dec 2024
- Type of study
- Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Allocetra-OTS
- Placebo
- Record updated
- 19 August 2025
Who can take part
- Age
- 18 years to 90 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Male or female ≥18 years and ≤90 years of age
- Meets Sepsis 3 criteria with a SOFA score ≥5 above pre-admission status
- Sepsis due to infection in at least one of the below organs:; 3.1. Community-Acquired Pneumonia (CAP). 3.2. Urinary tract infection 3.3. Acute cholecystitis diagnosed by Tokyo criteria 3.4. Acute cholangitis diagnosed by Tokyo criteria 3.5. Other intra-abdominal infections (IAI) 3.6. Skin or soft tissue infection
- Adequate source control
Who cannot take part
- Known immunocompromised state or medications known to be immunosuppressive
- Organ allograft or previous history of stem cell transplantation
- Sepsis due to infection other than lung infection, UTI, IAI, skin/soft tissue infection or sepsis patients where site of infection is unclear or unknown
- Patients with nosocomial infection
- A known malignancy
- Patients with end-stage disease (unrelated to sepsis)
- Known active symptomatic SARS-CoV-2 or chronic viral infections, such as HBV or HCV, HIV or other chronic infections
- Chronic respiratory disease
- Known NYHA class IV heart failure or unstable angina, ventricular arrhythmias, acute coronary disease or myocardial infarction
- On chronic dialysis
- Patients with acute pancreatitis
- Moribund patients
- Weight <50 kg or >120 kg or BMI >40 kg/m\^2
- SOFA score ≥14 at screening
- Known active upper GI tract ulceration or hepatic dysfunction
This trial has no sites in United States.
It has sites in 5 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
A Phase 2, Multi-Center, Randomized, Placebo-Controlled, Dose-Finding Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients
The 4 groups in the trial
- Cohort 1Placebo, for comparison
Single IV dose of placebo solution
Treatment: Placebo
- Cohort 2Treatment being tested
Single IV dose of 5x10\^9 Allocetra-OTS cells in suspension
Treatment: Allocetra-OTS
- Cohort 3Treatment being tested
Single IV dose of 10x10\^9 Allocetra-OTS cells in suspension
Treatment: Allocetra-OTS
- Cohort 4Treatment being tested
Single or two doses of 10x10\^9 Allocetra-OTS cells in suspension
Treatment: Allocetra-OTS
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2, Multi-Center, Randomized, Placebo-Controlled, Dose-Finding Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients
- Record updated
- 19 August 2025